FDA Investigator Rochelle K Kimmel

Rochelle K Kimmel has inspections in 12 countries as of 23 Oct 2023. Rochelle K Kimmel has collaborated with a combinined 3712 experts on various inspections, contributing to compliance and improvement across diverse sectors.

Investigator Details

Number of Inspected Sites:
34
Last Inspection Date:
23 Oct 2023
Investigator Role:
FDA Investigator
Redica ID:
Country:
China, United States of America, Israel, Denmark, Spain, Macao, Switzerland, Czechia, France, Canada, Sweden
Co-Investigator(s):
Adam R Cooke, Adetutu M Gidado, Alice S Tsao, Alicia M Mozzachio, Althea A Williams, Amatul H Marium, Amy M Cramer, Anastasia M Shields, Ann M Stewart, Ann Marie Montemurro, Ann Marie Schofield, Anthony A Charity, Arsen Karapetyan, Aziz A Mamur, Barbara Janine Breithaupt, Bijoy Panicker, Bing Cai, PhD, Brett R Havranek, Bruce H Mccullough, Carla J Lundi, Carol L Rehkopf, Caryn M Mcnab, Catherine J Laufmann, CDR Ileana Barreto Pettit, Charisse K Green, Chiang Syin, PhD, Christopher D Leach, Corey K Reno, Cynthia J Kee, Cynthia J Lee, MS, Cynthia Jim, CSO, Dandan Wang, PhD, Daniel J Grabicki, David K Lau, David M Beltran, David R Delucia, Delaram Moshkelani, Demitria J Xiradakis, Dennis Cantellops Paite, Donald L Lech, Dongping Dai, PhD, Douglas C Kovacs, Dr. Barbara D Paul, PhD, Dr. Chunchang Fang, Dr. Robert C Horan, MD, Edmund F Mrak, Jr, Edwin Melendez, Emest F Bizjak, Eric S Weilage, Erika V Butler, Erin D Mccaffery, Evan Tong, Felix Maldonado, Gary J Lehr, Gary L Pierce, George R Smith, George Smith, Gerald B Seaborn, Jr, Helen B Ricalde, Heriberto Negron Rivera, Iraida Ortiz, Iram R Hassan, PhD, Ivis Lnegron Torres, Jacqueline Mdiaz Albertini, Jacqueline S Warner, James A Liubicich, James A Liubieich, James C Maclaughlin, Jeffrey A Sommers, Jeffrey J Ebersole, Jennifer M Gogley, Jessica L Pressley, John D White, Jorge L Gonzalez, Jose A Lopez, Jose Acruz Gonzalez, Jose Alopez Rubet, Jose E Melendez, DDC, Jose O Hernandez, Jose R Hernandez, Joseph A Morkunas, Joshua P Wireman, Joy P Matthias, Juanita P Versace, Julianne C Mccullough, Julie D Bringger, Junho Pak, Karen E D'orazio, Karen K Morsnes, Karen Takahashi, Karishma G Gopaul, Karyn M Campbell, Katherine E Jacobitz, Katherine Szestypalow, Kelli F Dobilas, Kellia N Hicks, Kenneth H Williams, Kenneth M Gordon, Kevin A Gonzalez, Kham Phommachanh, Kim Lthomas Cruse, Kim Thomasc Rice, Kristy A Zielny, Larry K Austin, Laurie A Haxel, Lawrence Farine, Lawrence W Farina, Leonard H Lavi, Liatte Kreuger, PharmD, Libia M Lugo, Lisa B Hall, Lisa L Tung, Lori S Lawless, Lucas B Leake, Margaret M Annes, Marie Bbuen Bigornia, Matthew A Spataro, Matthew B Casale, Maya M Davis, Meisha R Sampson, Meisha Waters, Melissa J Garcia, Michael A Charles, Michael E Maselli, Michael Levin, Michael R Goga, Michael R Klapal, Michael S Araneta, Michele L Obert, Miguel A Martinez, Milva E Melendez, Mindy M Chou, Mra Davism, Mra Mcculloughj, Nancy L Rolli, Nasir Ali, PhD, Neil J Bonzagni, PhD MPH, Noreen Muniz, Parul M Patel, Paul A Bonneau, Paul L Bellamy, Paul L Figarole, Jr, Paul Mouris, Perry T Nichols, Peter Abel, Peter Caparelli, Peter E Baker, Peter R Caparelli, Prabhu P Raju, Pratik S Upadhyay, DDC, Rachael A Moliver, Rafael E Arroyo, Ralph A Erickson, Ramon A Hernandez, Raymond T Oji, Richard Ledwidge (nmi), PhD, Robert C Coleman, Robert C Steyert, Robert D Tollefsen, Robert J Doyle, Rodney D Combs, Ronald G Crawford, Rose M Ashley, Ruben C Ayala, PharmD, Russell J Glapion, Saied A Asbagh, Sandra A Hughes, Sarah E Mcmullen, Sarah E Rhoades, Satheesh Thomas, Scott T Ballard, Sean R Marcsisin, Seneca D Toms, Shari L Kahn, Sharon K Thoma, PharmD, Shelby N Marler, Simone E Pitts, Sony Mathews, Stacie A Woods, Stephen D Brown, Steven D Kehoe, Steven E Kane, Steven M Weinman, Steven P Donald, Steven Wienman, Susan F Laska, MS, Susan M Jackson, Susan W Ting, Susanna E Ford, Analyst, Susant Hadman, Syed N Ali, Syeda N Mahazabin, Tara G Bizjak, Thomas J Arista, Tiara Nbrown Crosen, Timothy T Kapsala, Torrance J Slayton, Truong Xuan Nguyen (Andy), Uduak M Inokon, Vanessa M Williams, Viviana Matta, Wanda B Coats, Wayne T Smith, Xiaokuang Lai, PhD, Xiaoping Guan, Youkeun Kim, Zachary L Miller, Zhong Li, PhD, Zhongren Wu

Rochelle K Kimmel's Documents

Publish Date Document Type Title
September, 2001 EIR The P.F. Laboratories Inc. - EIR, 2001-09-21
July, 2002 FDA 483 Teva Pharmaceutical Industries Ltd - Teva Tech - Form 483, 2002-07-31
February, 2002 FDA 483 Response Epic Pharma, LLC - Form 483R, 2002-03-07
March, 2000 FDA 483 Jiangsu Heingrui Pharmaceuticals Co., LTD - Form 483, 2000-03-07
November, 2001 EIR Fareva Pau - EIR, 2002-01-10
October, 2001 EIR Fougera Pharmaceuticals Inc. - EIR, 2001-10-18
December, 2000 EIR Omicron Quimica, S.A. - EIR, 2001-01-23
September, 2002 EIR Taro Pharmaceutical Laboratories, Inc. - EIR, 2002-09-19
December, 2002 EIR Delpharm Boucherville Canada Inc. - EIR, 2002-12-19
March, 2000 EIR Shaanxi Hanjiang Pharmaceutical Group Co., Ltd. - EIR, 2000-03-16
March, 2000 EIR Zhejiang Hisun Pharmaceutical Co., Ltd. - EIR, 2000-03-02
February, 2000 FDA 483 Hovione Macau Sociedade Quimica, Lda - Form 483, 2000-02-24
December, 2002 FDA 483 Delpharm Boucherville Canada Inc. - Form 483, 2002-12-19
December, 2000 FDA 483 Xellia Pharmaceuticals ApS - Form 483, 2000-12-06
December, 2002 FDA 483 Response Delpharm Boucherville Canada Inc. - Form 483R, 2003-01-30
August, 2002 FDA 483 Novetide Ltd. - Form 483, 2002-08-07
September, 2001 FDA 483 Response The P.F. Laboratories Inc. - Form 483R, 2001-09-26
October, 2001 FDA 483 Response Fougera Pharmaceuticals Inc. - Form 483R, 2001-10-25
February, 2002 FDA 483 Comercio De Primeras Materias Slu. - Form 483, 2002-02-21
July, 2002 FDA 483 Teva Pharmaceutical Industries Ltd. - Form 483, 2002-07-25
July, 2002 FDA 483 Response Teva Pharmaceutical Industries Ltd. - Form 483R, 2002-08-15
August, 2002 EIR Novetide Ltd. - EIR, 2002-12-18
December, 2000 EIR Xellia Pharmaceuticals ApS - EIR, 2000-12-06
November, 2002 FDA 483 Syntho Pharmaceuticals Inc. - Form 483, 2002-11-20
September, 2002 FDA 483 Taro Pharmaceutical Laboratories, Inc. - Form 483, 2002-09-19
March, 2000 FDA 483 Zhejiang Hisun Pharmaceutical Co., Ltd. - Form 483, 2000-03-02
December, 2000 FDA 483 Moehs Catalana SL - Form 483, 2000-12-14
July, 2002 EIR Assia Chemical Industries Ltd. - Teva Tech Site - EIR, 2002-07-31
December, 2000 FDA 483 Omicron Quimica, S.A. - Form 483, 2000-12-20
April, 2002 EIR Zhejiang Hisun Pharmaceutical Co., Ltd. - EIR, 2002-04-18
December, 2000 EIR Moehs Catalana SL - EIR, 2001-03-23
December, 2000 FDA 483 Response Xellia Pharmaceuticals ApS - Form 483R, 2001-01-10
December, 2000 FDA 483 Response Omicron Quimica, S.A. - Form 483R, 2001-06-11
August, 2002 FDA 483 Response Novetide Ltd. - Form 483R, 2002-09-02
February, 2000 EIR HOVIONE PHARMASCIENCE LIMITED - EIR, 2000-02-24
July, 2002 EIR Teva Pharmaceutical Industries Ltd. - EIR, 2002-07-25
September, 2002 FDA 483 Response Taro Pharmaceutical Laboratories, Inc. - Form 483R, 2002-11-27
November, 2001 FDA 483 Pierre Fabre Medicament Production - Form 483, 2001-11-30
November, 2002 FDA 483 Intermax Pharmaceuticals, Inc. - Form 483, 2002-11-20
July, 2002 FDA 483 Response Assia Chemical Industries Ltd. - Teva Tech Site - Form 483R, 2002-09-02
September, 2001 FDA 483 The P.F. Laboratories Inc. - Form 483, 2001-09-21
October, 2001 FDA 483 Fougera Pharmaceuticals Inc. - Form 483, 2001-10-18

Experience Redica System's NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more